Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
DLL3 (human) (rec.)
215
CHF
CHF 215.00
In stock
AG-40B-0151-C01010 µgCHF 215.00
AG-40B-0151-30103 x 10 µgCHF 430.00
| Product Details | |
|---|---|
| Synonyms | Delta-like Protein 3; Delta3; Drosophila Delta Homolog 3 |
| Product Type | Protein |
| Properties | |
| Source/Host | HEK 293 cells |
| Sequence |
Extracellular domain of human DLL3 (aa 27-466) is fused at the N-terminus to a FLAG®-tag. |
| Crossreactivity | Human |
| MW | ~52kDa (SDS-PAGE) |
| Purity | ≥95% (SDS-PAGE) |
| Endotoxin Content | <0.01EU/μg purified protein (LAL test). |
| Concentration | 0.1 mg/ml after reconstitution. |
| Reconstitution | Reconstitute with 100μl sterile water. |
| Formulation | Lyophilized. Contains PBS |
| Other Product Data |
UniProt link Q9NYJ7: DLL3 (human) |
| Shipping and Handling | |
| Shipping | BLUE ICE |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
After reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. Centrifuge lyophilized vial before opening and reconstitution. PBS containing at least 0.1% BSA should be used for further dilutions. |
| Use/Stability |
Stable for at least 6 months after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
DLL3 (Delta-like protein 3; Delta3) inhibits primary neurogenesis. It plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm. DLL3 binds and activates Notch-1. Defects in DLL3 are the cause of spondylocostal dysostosis type 1 (SCDO1).
Product References
- Design and Validation of Inducible TurboCARs with Tunable Induction and Combinatorial Cytokine Signaling: RJ. Lin, et al.; Cancer Immunol. Res. 10, 1069 (2022)
- Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer: Y. Zhang, et al.; Clin. Cancer Res. 29, 971 (2023)
Related Products
